HIV

Adolescents and young adults who are living with HIV and were exposed to the virus perinatally have a unique risk of nonadherence in adolescence, as well as an elevated risk of mental health and substance use problems.

Only 21% of HIV-positive individuals visited a health care provider within 2 weeks of release from jail or prison.

Vaccine regimen based on mosaic immunogens designed to create a buffer against various strains of HIV.

Voluntary male circumcision and starting antiretroviral therapy reduced new cases of HIV by 42% in vulnerable regions.

THC found to slow the process of neurodegeneration, which affects nearly half of all patients with HIV.

Long-acting pre-exposure prophylaxis may improve adherence to HIV treatment.

These findings could lead to novel a HIV vaccine.

Nearly 30,000 individuals were diagnosed with HIV in the European Region in 2016.

An investigational HIV drug may be able to cross the blood-brain barrier and prevent adverse events.

Doctors are less likely to prescribe common cardiovascular prevention and intervention therapies to HIV-positive patients.

Starting an adherence program for patients with HIV may mitigate costs for universal treatment protocols.

Age-related health issues affect people living with HIV infection at an accelerated rate.

A second HIV test may avoid significant costs.

Nearly 21 million individuals with HIV had access to antiretroviral therapy (ART) in June 2017 compared to 685,000 HIV-positive patients in 2000.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Raltegravir (Isentress) is an integrase inhibitor for use in combination with other antiretroviral agents for HIV-1 in newborn infants weighing at least 2 kg.

Millions of individuals gain access to HIV treatment, but there are significant gaps that need to be addressed to end the epidemic.

Americans are getting tested and diagnosed with HIV sooner after infection, according to a recently-published CDC Vital Signs report.

Closing gaps in testing at-risk populations could increase HIV diagnoses.

Increased virologic failure and drug resistance following dolutegravir monotherapy prompt researchers to recommend against its use in patients with HIV.

Top news of the week from Specialty Pharmacy Times.

Juluca can replace ART in patients with HIV.

Juluca is indicated as a complete therapy for patients with HIV-1.

Juluca is indicated as a complete therapy for patients with HIV-1.

Many immunotherapy clinical trials exclude HIV-positive patients with cancer.

HIV-positive patients need to maintain healthy body weight, quit smoking, eat well, exercise regularly and treat hypertension, diabetes and dyslipidemia.

Health care stakeholders need to do a better job of adjusting testing and treatment to follow the HIV epidemic.

Identification of the last unknown protein in HIV could lead to a cure for the virus.